Department of Radiation Oncology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland, USA.
Department of Radiation Oncology, Brown University, Providence, Rhode Island, USA.
J Appl Clin Med Phys. 2024 Oct;25(10):e14485. doi: 10.1002/acm2.14485. Epub 2024 Aug 27.
A single treatment planning system (TPS) model for matched linacs provides flexible clinical workflows from patient treatment to intensity-modulated radiation therapy (IMRT) quality assurance (QA) measurement. Since general guidelines for building a single TPS model and its validation for matched linacs are not well established, we present our RayStation photon TPS modeling strategy for matched Elekta VersaHD linacs.
The four linacs installed from 2013 to 2020 were matched in terms of Percent Depth Dose (PDD), profile, output factor and wedge factors for 6-MV, 10-MV, 15-MV, and 6-MV-FFF, and maintained following TG-142 recommendations until RayStation commissioning. The RayStation single model was built to represent all four linacs within the tolerance limits recommended by MPPG-5.a. The comprehensive validation tests were performed for one linac following MPPG-5.a and TG-119 guidelines, and spot checks for the other three. Our TPS modeling/validation method was evaluated by re-analyzing the previous 103 patient-specific IMRT/volumetric modulated arc therapy (VMAT) QA measurements with the calculated planar doses by the single model in comparison with the analysis results using four individual Pinnacle TPS models.
For all energies, our single model PDDs were within 1% agreement of the four-linac commissioning measurements. The MPPG-5.a validation tests from 5.1 through 7.5 and all TG-119 measurements passed within the recommended tolerance limits. The IMRT QA results (mean ± standard deviation) for RayStation single model versus Pinnacle individual models were 98.9% ± 1.3% and 98.0% ± 1.4% for 6-MV, 99.9% ± 0.1% and 99.1% ± 1.9% for 10-MV, and 98.2% ± 1.3% and 97.9% ± 1.8% for 6-MV-FFF, respectively.
We successfully built and validated a single photon beam model in RayStation for four Elekta Linacs. The proposed new validation methods were proven to be both efficient and effective.
用于匹配直线加速器的单一治疗计划系统(TPS)模型提供了灵活的临床工作流程,从患者治疗到强度调制放射治疗(IMRT)质量保证(QA)测量。由于尚未建立用于构建单一 TPS 模型及其用于匹配直线加速器的验证的一般准则,因此我们介绍了用于匹配 Elekta VersaHD 直线加速器的 RayStation 光子 TPS 建模策略。
2013 年至 2020 年安装的四台直线加速器在 6-MV、10-MV、15-MV 和 6-MV-FFF 的百分深度剂量(PDD)、轮廓、输出因子和楔形因子方面进行了匹配,并按照 TG-142 建议进行了维护,直到 RayStation 调试。在 MPPG-5.a 推荐的公差范围内,构建了 RayStation 单一模型以代表所有四台直线加速器。根据 MPPG-5.a 和 TG-119 指南对一台直线加速器进行了全面的验证测试,并对另外三台进行了抽查。我们的 TPS 建模/验证方法通过使用单一模型计算的平面剂量对先前的 103 个患者特定的调强放射治疗/容积调强弧形治疗(VMAT)QA 测量值进行重新分析,并与使用四个单独的 Pinnacle TPS 模型进行分析的结果进行了评估。
对于所有能量,我们的单一模型 PDD 在与四台直线加速器调试测量值的 1%以内。在推荐的公差范围内,通过了 MPPG-5.a 验证测试从 5.1 到 7.5 以及所有 TG-119 测量。RayStation 单一模型与 Pinnacle 单个模型的 IMRT QA 结果(平均值±标准偏差)分别为 6-MV 为 98.9%±1.3%和 98.0%±1.4%,10-MV 为 99.9%±0.1%和 99.1%±1.9%,6-MV-FFF 为 98.2%±1.3%和 97.9%±1.8%。
我们成功地在 RayStation 中为四台 Elekta 直线加速器构建和验证了一个单一的光子束模型。所提出的新验证方法被证明既高效又有效。